Burning Rock Biotech Stock Forecast, Price & News

+0.36 (+1.58 %)
(As of 08/2/2021 10:04 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,400 shs
Average Volume373,612 shs
Market Capitalization$2.42 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BNR News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

Burning Rock Biotech logo

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.60 out of 5 stars

Business Services Sector

259th out of 553 stocks

Medical Laboratories Industry

20th out of 41 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Burning Rock Biotech (NASDAQ:BNR) Frequently Asked Questions

Is Burning Rock Biotech a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Burning Rock Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Burning Rock Biotech stock.
View analyst ratings for Burning Rock Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Burning Rock Biotech?

Wall Street analysts have given Burning Rock Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Burning Rock Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Burning Rock Biotech's next earnings date?

Burning Rock Biotech is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Burning Rock Biotech

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) released its quarterly earnings results on Monday, May, 24th. The company reported ($1.65) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.50) by $0.15. The business had revenue of $16.27 million for the quarter. Burning Rock Biotech had a negative net margin of 112.99% and a negative trailing twelve-month return on equity of 21.52%.
View Burning Rock Biotech's earnings history

What guidance has Burning Rock Biotech issued on next quarter's earnings?

Burning Rock Biotech updated its FY 2021 earnings guidance on Tuesday, June, 22nd. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $93.10 million-93.10 million, compared to the consensus revenue estimate of $94.29 million.

What price target have analysts set for BNR?

1 brokerages have issued 1 year price objectives for Burning Rock Biotech's stock. Their forecasts range from $39.94 to $39.94. On average, they expect Burning Rock Biotech's stock price to reach $39.94 in the next twelve months. This suggests a possible upside of 75.3% from the stock's current price.
View analysts' price targets for Burning Rock Biotech
or view top-rated stocks among Wall Street analysts.

Who are Burning Rock Biotech's key executives?

Burning Rock Biotech's management team includes the following people:
  • Dr. Shaokun Chuai, COO & Director (Age 42)
  • Mr. Yusheng Han, Founder, Chairman & CEO (Age 42)
  • Mr. Jinxiang Li, CFO, Compliance Officer & Director (Age 36)
  • Dr. Zhihong Zhang, Chief Technology Officer (Age 45)
  • Mr. Hao Liu, Sr. Advisor (Age 47)

Who are some of Burning Rock Biotech's key competitors?

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

When did Burning Rock Biotech IPO?

(BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

What is Burning Rock Biotech's stock symbol?

Burning Rock Biotech trades on the NASDAQ under the ticker symbol "BNR."

Who are Burning Rock Biotech's major shareholders?

Burning Rock Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.83%), E Fund Management Hong Kong Co. Ltd. (0.10%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%).

Which institutional investors are buying Burning Rock Biotech stock?

BNR stock was purchased by a variety of institutional investors in the last quarter, including E Fund Management Hong Kong Co. Ltd., Zurcher Kantonalbank Zurich Cantonalbank , and Sumitomo Mitsui Trust Holdings Inc..

How do I buy shares of Burning Rock Biotech?

Shares of BNR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Burning Rock Biotech's stock price today?

One share of BNR stock can currently be purchased for approximately $22.78.

How much money does Burning Rock Biotech make?

Burning Rock Biotech has a market capitalization of $2.38 billion and generates $65.89 million in revenue each year. The company earns $-62,410,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Burning Rock Biotech have?

Burning Rock Biotech employs 938 workers across the globe.

What is Burning Rock Biotech's official website?

The official website for Burning Rock Biotech is

Where are Burning Rock Biotech's headquarters?

Burning Rock Biotech is headquartered at 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005.

How can I contact Burning Rock Biotech?

Burning Rock Biotech's mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The company can be reached via phone at 86 20 3403 7871.

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.